Abstract | INTRODUCTION: AREAS COVERED: This review analyzes the present literature for immunotherapy of PC. Advances from immune stimulators, radionucleotide-conjugated- and bispecific antibodies to future developments like adoptive engineered T-cells with chimeric receptors are discussed. The clinical development of catumaxomab, which was the first intraperitoneal immunotherapy to be approved for clinical treatment, is discussed. The requirements for future developments are illustrated. Expert commentary: Immunotherapy of peritoneal carcinomatosis is manageable, showing striking cancer cell killing. Improved profiles of adverse events by therapy-induced cytokine release, enhanced specific killing and optimal treatment schedules within multimodal treatment will be key factors.
|
Authors | Michael Alfred Ströhlein, Markus Maria Heiss, Karl-Walter Jauch |
Journal | Expert review of anticancer therapy
(Expert Rev Anticancer Ther)
Vol. 16
Issue 10
Pg. 1019-27
(Oct 2016)
ISSN: 1744-8328 [Electronic] England |
PMID | 27530056
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antibodies, Bispecific
- Cytokines
- catumaxomab
|
Topics |
- Animals
- Antibodies, Bispecific
(administration & dosage, adverse effects, therapeutic use)
- Combined Modality Therapy
- Cytokines
(immunology)
- Cytoreduction Surgical Procedures
(methods)
- Humans
- Hyperthermia, Induced
(methods)
- Immunotherapy
(adverse effects, methods)
- Peritoneal Neoplasms
(immunology, therapy)
|